Evidence map›Paper›PMID 42477307›Full record

ArticleJournal of natural medicines2026

Quercetin attenuates cisplatin-induced muscle atrophy via Hippo/YAP1 signaling pathway.

Jingchun Lv, Jianwei Lin, Xiaojing Chen, Qi Wu, Zhiyao Cao, Dapeng Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingchun LvDepartment of Oncology (Ward 2), Shanghai Childrens Medical Center, Shanghai Jiao Tong University, Shanghai, China.
Jianwei LinDepartment of Oncology (Ward 2), Shanghai Childrens Medical Center, Shanghai Jiao Tong University, Shanghai, China.
Xiaojing ChenDepartment of Oncology (Ward 2), Shanghai Childrens Medical Center, Shanghai Jiao Tong University, Shanghai, China.
Qi WuDepartment of Oncology (Ward 2), Shanghai Childrens Medical Center, Shanghai Jiao Tong University, Shanghai, China.
Zhiyao CaoDepartment of Oncology (Ward 2), Shanghai Childrens Medical Center, Shanghai Jiao Tong University, Shanghai, China.
Dapeng JiangDepartment of Oncology (Ward 2), Shanghai Childrens Medical Center, Shanghai Jiao Tong University, Shanghai, China. jdp509@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscle wasting is a common event among cancer patients receiving chemotherapy treatment and has been reported to affect their survival. However, current therapies for counteracting this side effect are ineffective. This study investigates quercetin's efficacy against cisplatin-induced muscle atrophy and its mechanism. Using both C2C12 myotube and mouse models, we found quercetin pretreatment significantly alleviates cisplatin-induced muscle wasting. Mechanistically, transcriptome analysis identified that the Hippo signaling pathway was involved in cisplatin-induced muscle atrophy. Quercetin restored the activity of this pathway, including the expression and nuclear localization of its effector YAP1. Furthermore, quercetin mitigated cisplatin-induced muscle damage by improving mitochondrial membrane quality and function. Molecular docking revealed a direct interaction between quercetin and YAP1. Additionally, the possible interaction between YAP1 and mitochondrial function was revealed. Our findings demonstrate that quercetin attenuates cisplatin-induced muscle atrophy by modulating the Hippo/YAP1 pathway and preserving mitochondrial homeostasis, highlighting its therapeutic potential.

Indexed as

CisplatinMitochondrial dysfunctionMuscle atrophyQuercetinYAP1

Identifiers

PMID42477307

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.